Research programme: cannabinoids - Peak Pharmaceuticals

Drug Profile

Research programme: cannabinoids - Peak Pharmaceuticals

Latest Information Update: 19 Jan 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cannabis Therapy Corp
  • Developer Peak Pharmaceuticals
  • Class Cannabinoids
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders; Inflammation

Most Recent Events

  • 19 Jan 2015 Cannabis Therapy Corp is now Peak Pharmaceuticals
  • 08 Jul 2014 Early research in Autoimmune disorders in USA (unspecified route)
  • 08 Jul 2014 Early research in Inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top